Search
MoonLake Immunotherapeutics
MLTXAdd to Watchlist
18.983USD
-0.147-0.77%
Market hours （ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
16
analysts
Buy
Current Rating
31.000
Target Price
+59.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
MoonLake Immunotherapeutics
MLTX
16
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
How have MoonLake ImmunotherapeuticsMLTX's recent earnings per share performed?
The market expectation was USD -0.98, while MoonLake ImmunotherapeuticsMLTX's earnings per share (EPS) for the previous quarter was USD -0.92. EPS for the next quarter is expected at USD -0.94.
What is the analyst rating for MoonLake Immunotherapeutics?
Based on the ratings of MoonLake Immunotherapeutics's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.